한글목차

세프록심 세계 시장 규모는 2024년 5억 3,088만 달러에서 2030년에는 8억 4,401만 달러에 달할 것으로 예상되며, 예측 기간 동안 5.10%의 연평균 성장률(CAGR)을 보일 것으로 예측됩니다.

이 시장은 주로 세플록심의 광범위한 항균 특성과 호흡기 및 요로 감염에 대한 효과적인 치료법에 대한 수요 증가로 인해 완만하지만 꾸준히 성장하고 있습니다.

2세대 세팔로스포린계 항생제인 세플록심은 그람양성균과 그람음성균 모두에 효과적이기 때문에 널리 처방되고 있습니다. 기관지염, 부비동염, 폐렴, 중이염, 각종 피부 감염 등의 치료에 자주 사용되며, 전 세계 항균제 치료에서 중요한 역할을 하고 있습니다.

시장 개척은 특히 헬스케어 인프라가 빠르게 변화하고 있는 신흥국 시장의 감염병 발병률 증가로 인해 더욱 촉진될 것입니다.

주요 시장 성장 촉진요인

세계 헬스케어 부문 확대

주요 시장 이슈

항생제 내성 증가

주요 시장 동향

세균 감염 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 세프록심 시장에 미치는 영향

제5장 세계의 세프록심 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 판매채널별(직접, 간접)
  • 등급별(아키세틸, 나트륨)
  • 용도별(기관지염, 임질, 라임병, 피부 감염증, 귀 감염증, 인후 감염증, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 세프록심 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 세프록심 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 세프록심 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 세프록심 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 세프록심 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 세프록심 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Anhui BBAC Likang Pharmaceutical Co., Ltd.
• Zhuhai United Laboratories Co.
• Nectar Lifesciences Ltd.
• Dhanuka Laboratories Pvt Ltd
• Aurobindo Pharma Limited
• Covalent laboratories private limited
• Orchid Pharma
• Akums drugs & pharmaceuticals ltd
• Lupin Limited
• Hetero Labs Ltd

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Cefuroxime market was valued at USD 530.88 million in 2024 and is projected to reach USD 844.01 million by 2030, growing at a compound annual growth rate (CAGR) of 5.10% during the forecast period. The market is witnessing moderate yet consistent growth, primarily driven by Cefuroxime's broad-spectrum antibacterial properties and the rising need for effective treatments for respiratory and urinary tract infections.

As a second-generation cephalosporin antibiotic, Cefuroxime is widely prescribed due to its efficacy against both Gram-positive and Gram-negative bacteria. It is commonly utilized in the treatment of conditions such as bronchitis, sinusitis, pneumonia, otitis media, and various skin infections, thereby playing a vital role in global antimicrobial therapy.

Market growth is further fueled by the increasing incidence of infectious diseases, particularly in developing regions where healthcare infrastructure is undergoing rapid transformation.

Key Market Drivers

Expansion of the Global Healthcare Sector

The ongoing growth of the global healthcare industry significantly contributes to the Cefuroxime market's expansion. The hospital segment alone accounted for approximately 40% of the global healthcare market in 2022, with a value exceeding USD 3.9 trillion. This figure is expected to rise to 44% by 2029, reaching a projected market size of USD 5.19 trillion. As hospitals increasingly become central to healthcare delivery, the demand for broad-spectrum antibiotics such as Cefuroxime continues to grow in tandem with healthcare infrastructure improvements, enhanced access to medical services, and evolving treatment protocols.

Cefuroxime is widely utilized in the management of a broad range of bacterial infections, including respiratory tract infections, skin infections, urinary tract infections, and for surgical prophylaxis. As such, it remains an indispensable part of modern antimicrobial therapy.

Key Market Challenges

Rising Antibiotic Resistance

One of the most significant challenges facing the global Cefuroxime market is the increasing prevalence of antibiotic resistance, which is undermining the effectiveness of many broad-spectrum antibiotics, including second-generation cephalosporins. As bacterial strains develop mechanisms to resist antibiotic treatment, the therapeutic reliability of Cefuroxime is being compromised in certain indications.

This trend has led to a more cautious approach to antibiotic prescribing, in alignment with international antimicrobial stewardship efforts, potentially reducing prescription volumes in favor of newer, more targeted therapies. The emergence of multidrug-resistant bacteria presents a growing threat to public health, highlighting the need for innovation in antibiotic development. As an established molecule, Cefuroxime faces limitations in this evolving landscape, presenting both clinical and commercial challenges for pharmaceutical companies striving to balance responsible antibiotic use with sustained product viability.

Key Market Trends

Increasing Incidence of Bacterial Infections

The global rise in bacterial infections represents a key trend shaping the Cefuroxime market's growth trajectory. Bacterial infections are responsible for approximately 7.7 million deaths annually, accounting for one in every eight fatalities and ranking as the second leading cause of death worldwide. Alarmingly, nearly 5 million of these deaths are linked to antibiotic-resistant bacterial strains, highlighting the critical threat posed by antimicrobial resistance.

This escalating public health issue has driven heightened demand for broad-spectrum antibiotics like Cefuroxime, particularly in healthcare settings managing high incidences of respiratory, urinary tract, and skin and soft tissue infections. As a result, Cefuroxime continues to play a vital role in both inpatient and outpatient antimicrobial treatment strategies.

Key Market Players

• Anhui BBAC Likang Pharmaceutical Co., Ltd.
• Zhuhai United Laboratories Co.
• Nectar Lifesciences Ltd.
• Dhanuka Laboratories Pvt Ltd
• Aurobindo Pharma Limited
• Covalent laboratories private limited
• Orchid Pharma
• Akums drugs & pharmaceuticals ltd
• Lupin Limited
• Hetero Labs Ltd

Report Scope

In this report, the Global Cefuroxime Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefuroxime Market, By Sales Channel:

• Direct
• Indirect

Cefuroxime Market, By Grade:

• Axetil
• Sodium

Cefuroxime Market, By End Use:

• Bronchitis
• Gonorrhea
• Lyme Disease
• Skin Infection
• Ear Infection
• Throat Infection
• Others

Cefuroxime Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefuroxime Market.

Available Customizations:

Global Cefuroxime Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cefuroxime Market

5. Global Cefuroxime Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By Grade (Axetil, Sodium)
  • 5.2.3. By End Use (Bronchitis, Gonorrhea, Lyme Disease, Skin Infection, Ear Infection, Throat Infection, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Cefuroxime Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By Grade
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cefuroxime Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By Grade
      • 6.3.1.2.3. By End Use
  • 6.3.2. Mexico Cefuroxime Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By Grade
      • 6.3.2.2.3. By End Use
  • 6.3.3. Canada Cefuroxime Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By Grade
      • 6.3.3.2.3. By End Use

7. Europe Cefuroxime Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By Grade
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cefuroxime Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By Grade
      • 7.3.1.2.3. By End Use
  • 7.3.2. Germany Cefuroxime Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By Grade
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Cefuroxime Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By Grade
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Cefuroxime Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By Grade
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Cefuroxime Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By Grade
      • 7.3.5.2.3. By End Use

8. Asia Pacific Cefuroxime Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By Grade
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cefuroxime Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By Grade
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Cefuroxime Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By Grade
      • 8.3.2.2.3. By End Use
  • 8.3.3. South Korea Cefuroxime Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By Grade
      • 8.3.3.2.3. By End Use
  • 8.3.4. Japan Cefuroxime Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By Grade
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Cefuroxime Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By Grade
      • 8.3.5.2.3. By End Use

9. South America Cefuroxime Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By Grade
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cefuroxime Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By Grade
      • 9.3.1.2.3. By End Use
  • 9.3.2. Argentina Cefuroxime Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By Grade
      • 9.3.2.2.3. By End Use
  • 9.3.3. Colombia Cefuroxime Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By Grade
      • 9.3.3.2.3. By End Use

10. Middle East and Africa Cefuroxime Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By Grade
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cefuroxime Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By Grade
      • 10.3.1.2.3. By End Use
  • 10.3.2. Saudi Arabia Cefuroxime Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By Grade
      • 10.3.2.2.3. By End Use
  • 10.3.3. UAE Cefuroxime Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By Grade
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cefuroxime Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Anhui BBAC Likang Pharmaceutical Co., Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Zhuhai United Laboratories Co.
• 15.3. Nectar Lifesciences Ltd.
• 15.4. Dhanuka Laboratories Pvt Ltd
• 15.5. Aurobindo Pharma Limited
• 15.6. Covalent laboratories private limited
• 15.7. Orchid Pharma
• 15.8. Akums drugs & pharmaceuticals ltd
• 15.9. Lupin Limited
• 15.10. Hetero Labs Ltd

16. Strategic Recommendations

17. About Us & Disclaimer